Mumbai Angels (MA) Network launched the LifeSciences Vertical in February 2020,to provide a single platform for Startups, Corporates, Investors and Institutions in the segment to collaborate, share knowledge and grow. We are seeing an increasing interest from our network of angel investors in lifesciences who are keen to participate in the growth story of new age pharma/healthcare companies. In the backdrop of the pandemic and the ever increasing need to understand the challenges and opportunities in this segment, MA Network organized our First Virtual Conference on LifeSciences Sector on 27th March 2020 which was specially organized for Corporates, Investors, Startups, Institutions and Enablers from the domain. The panel, comprised of sector experts and stalwarts shared their thoughts on how stakeholders will have to contribute to make India a Global LifeSciences Role Model. See More In June, Delhi-based medtech startup Crimson Healthcare raised Rs 1.75 Cr from Mumbai Angels Network Read More & in September, biotech startup Mestastop raised successful funding Read More On 28th August 2020, MA Network organised a large format Lifesciences Virtual Summit - a 3 hour Conference with panel discussions across Biotech, Healthtech and Pharma solutions transforming the LifeSciences sector. The event was well attended by C-level executives and decision makers from companies, large corporations, innovative start-ups, angel investors and venture capitalists. WIth having Dr Krishna Ella, Bharat Biotech and Manish Gupta, Indegene as Keynote Speakers. Santosh Marathe, Apollo Hospitals, Navi Mumbai; Niraj Didwania, HealthCare Global (HCG); Monika Sood, Arete Advisors; Dr Oommen John, Asia Pacific Association for Medical Informatics, Chhitiz Kumar, Phillips; Manish Gupta, Sequent Scientific; Rema Subramanian, Ankur Capital Fund; Amitvikram Sharma, Claris Capital Limited; Venkat Bundla, Garphi Biosciences Pvt Ltd; TCM Sundaram, Chiratae Ventures India; Dr R Kishore Kumar, Cloudnine Group of Hospitals and many others shared their insights with an eager audience. |
No comments:
Post a Comment